[Role of biologically active agents in the pathogenesis of proliferative vitreoretinopathy].
Boĭko
E V
EV
Roshkius
V P
VP
D016207:Cytokines / Q000378:metabolism / Q000502:physiology*; D005346:Fibroblast Growth Factors / Q000378:metabolism / Q000502:physiology; D005353:Fibronectins / Q000378:metabolism / Q000502:physiology; D006801:Humans; D007378:Interleukins / Q000378:metabolism / Q000502:physiology; D010982:Platelet-Derived Growth Factor / Q000378:metabolism / Q000502:physiology; D017479:Receptors, Platelet-Derived Growth Factor / Q000378:metabolism; D055213:Retinal Pigment Epithelium / Q000378:metabolism / Q000502:physiology; D016211:Transforming Growth Factor alpha / Q000378:metabolism / Q000502:physiology; D016212:Transforming Growth Factor beta / Q000378:metabolism / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism / Q000502:physiology; D018630:Vitreoretinopathy, Proliferative / Q000209:etiology* / Q000378:metabolism
D016207:Cytokines; D005353:Fibronectins; D007378:Interleukins; D010982:Platelet-Derived Growth Factor; D016211:Transforming Growth Factor alpha; D016212:Transforming Growth Factor beta; D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors; D017479:Receptors, Platelet-Derived Growth Factor